NYSE:MDTMedical Equipment
Assessing Medtronic’s Valuation After FDA Approval Expands OmniaSecure Defibrillation Lead Use
Medtronic (MDT) is back in focus after securing U.S. FDA approval to expand use of its OmniaSecure defibrillation lead to the heart’s left bundle branch area, widening potential applications in conduction system pacing.
See our latest analysis for Medtronic.
The FDA approval comes as Medtronic’s share price, now at $87.17, reflects a 1-day share price return of 1.17%, a 30-day share price return of 10% and a year-to-date share price return of 9.25%. The 3-year total shareholder return of...